Farah joined Alta in 2000. She currently serves on the board of directors of Chimerix, Portola Pharmaceuticals and Trevena. Farah also led Alta’s investments in Achaogen, Agensys, Cytokinetics, Esperion Therapeutics, Excaliard Pharmaceuticals, Orphan Medical and Renovis.
Prior to Alta, Farah was an investment banker at Robertson Stephens & Company between 1987 and 1999, where she focused on biotechnology and other life sciences companies. She was elected a General Partner in 1992 and head of the global life sciences investment banking group in 1995. During that time, she was responsible for building one of the most successful life sciences investment banking franchises on Wall Street.
She holds a Master of Business Administration from Stanford University and a Bachelor of Arts in Economics from Smith College.